MRD-guided treatment cessation in multiple myeloma
- PMID: 37776871
- DOI: 10.1016/S2352-3026(23)00240-5
MRD-guided treatment cessation in multiple myeloma
Conflict of interest statement
BAD has received honoraria for advisory board activity for Janssen Pharmaceuticals and Cota and serves as an independent reviewer of a clinical trial for BMS.
Comment on
-
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.Lancet Haematol. 2023 Nov;10(11):e890-e901. doi: 10.1016/S2352-3026(23)00236-3. Epub 2023 Sep 27. Lancet Haematol. 2023. PMID: 37776872 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical